This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arrayit Corporation Reports Strong Surge In Customer Demand For The Company's Leading Edge Life Sciences Microarray Instruments

SUNNYVALE, Calif., May 10, 2010 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC), a leader in life sciences and healthcare technology, reports today a strong surge in customer demand for the company's leading edge life sciences microarray instruments. On Friday May 7th, the company quoted 17 instruments representing $1.2M in total revenue. The increase coincides directly with the first deliveries of the new Arrayit 2010 catalog sent by mail to 11,000 life sciences professionals worldwide.

Arrayit Corporation CEO Rene Schena stated, "We are pleased by the positive and immediate customer response. Our commitment to life sciences instrumentation is an important driver for revenues growth in 2010." 

Arrayit's life sciences instruments empower scientists and clinicians to explore fundamental challenges in basic research, agriculture, and medicine, including deciphering the molecular basis of human diseases. Arrayit microarrays are manufactured by depositing nearly invisible spots of genes, proteins, and patient DNAs onto glass substrates, and then reacting the microarrays with labeled samples isolated from living cells and other sources. The microarrays are processed and read using computer-controlled hybridization stations and high-speed fluorescence scanners to produce digital genomic and proteomic data. Arrayit's instruments are "best-in-class" based on unparalleled performance, versatility, and ease-of-use. 

Arrayit Corporation President and Chief Science Officer Mark Schena said, "The widely adopted Arrayit platform with its unique technological attributes, including the proprietary H25K complete human genome chip, provides results that are unrivaled by other platforms. Arrayit microarrays and instruments offer richer content and greater sensitivity than competing platforms, and these attributes have allowed us to discover the world's only definitive pre-symptomatic biomarkers for ovarian cancer and Parkinson's Disease, as well as a new pharmaceutically important pathway in human biology that will be the subject of future announcements." 

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products and services to a customer base of more than 10,000 clinics and research facilities and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information. 

Safe Harbor Statement

We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2009.

CONTACT:  Arrayit Corporation
          Investor Relations
          408-744-1331
          investorrelations@arrayit.com

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,014.57 -16.57 -0.10%
S&P 500 1,981.39 -2.74 -0.14%
NASDAQ 4,506.5930 -12.3090 -0.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs